Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... with anemia were treated with red blood cell transfusion and red blood cell growth factors. The first clinical trial ... trial found 67% achieved red blood cell transfusion independence . Red blood cell transfusion independence was achieved in a ...

    Research Review last updated 05/02/2016 - 9:12am.

  2. Nursing Education Modules on MDS Disease Management and Patient Education

    ... therapy, minimal toxicity, improvement of blood counts, transfusion independence , delay of leukemic transformation, improved survival, quality ...

    Page last updated 04/27/2015 - 2:44pm.

  3. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... who were treated with lenalidomide achieved sustained independence from RBC transfusions.  Moreover, most patients saw either ... treatment affords many patients a sustained RBC transfusion independence and a significant cytogenetic response. ... younger patients, as reflected by equivalent rates of RBC transfusion-independence, cytogenetic response, and AML progression. While ...

    Research Review last updated 05/02/2016 - 9:32am.

  4. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q ... clinical benefits included high rates of RBC-transfusion independence (TI) with prolonged durations of response, high rates of ...

    Research Article last updated 12/08/2015 - 1:06pm.

  5. A Phase 1 Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate 1 Risk Myelodysplastic Syndromes

    ... patients experiencing bilineage responses. Three of 25 RBC transfusion-dependent (TD) patients achieved transfusion independence (TI) and 5 of 7 platelet TD patients achieved TI. ...

    Research Article last updated 01/20/2015 - 1:07pm.

  6. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

    ... the health-related quality of life (HRQOL) in lower-risk, transfusion-dependent patients with myelodysplastic syndromes (MDS) ... predictive factor of an earlier achievement of transfusion independence with a HR of 1.032 (99% CI 1.004 to 1.060; p=0.003). ...

    Research Article last updated 09/24/2014 - 10:50am.

  8. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... overall survival. Quality of life, symptom control, and transfusion independence are also important. The National Comprehensive Cancer Network ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

    ... the goals of maintaining donor hematopoiesis and transfusion independence while decreasing early and late complications of HCT for DC. ...

    Clinical Trial last updated 04/27/2016 - 8:49am.

  10. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... hypomethylating agent with a meaningful benefit (such as transfusion independence ) or a larger benefit (like complete remission) with subsequent ...

    Interview last updated 06/17/2014 - 9:15am.